BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $19 from $20 and keeps a Neutral rating on the shares. The firm updated operating expense trends and share count after a Q1 report that it says was “largely consistent with our updated view post HAELO data.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
- Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
- Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
- Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today
- Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline